糖尿病驱动的瘤发生和重用抗糖尿病药物的抗癌潜力:系统性审查
Iqra Khan1, Aisha Kamal2, Salman Akhtar1
1Department of Bioengineering, Integral University, Lucknow, 226026, Uttar Pradesh, India.
Cell biochemistry and biophysics
|July 2, 2024
概括
糖尿病通过改变新陈代谢和促进瘤生长来促进癌症的进展. 重新定位糖尿病药物可能通过针对这些共同途径提供新的癌症治疗方法.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
背景情况:
- 糖尿病和癌症是全球死亡的主要原因.
- 糖尿病和各种癌症类型之间存在复杂的病理联系.
- 癌细胞通过多种机制表现出耐药性.
研究的目的:
- 审查糖尿病和癌症之间的病理关联.
- 探索将这两种疾病联系在一起的分子机制.
- 在它们的交叉点确定潜在的治疗策略.
主要方法:
- 关于病理学关联的文献评论.
- 分子机制 (代谢,信号通路) 的分析.
- 检查葡萄糖代谢,糖化和AGE/RAGE轴在瘤发生中的作用.
主要成果:
- 糖尿病中葡萄糖代谢的改变促进了癌症的特征,如扩散和转移.
- 先进的糖化终端产物 (AGEs) 和它们的受体 (RAGE) 与癌症病因和进展有关.
- 重新编程葡萄糖代谢是癌症发展的一个关键特征.
结论:
- 糖尿病作为癌症进展的显著调节器.
- 重新改造的抗糖尿病药物显示出作为癌症对策的潜力.
- 为了在糖尿病和癌症的交叉点上取得治疗进展,需要进一步的研究.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


